These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441 [TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma. Badri N; Ngamdu KS; Torabi A; Guar S J Cancer Res Ther; 2020; 16(1):183-185. PubMed ID: 32362635 [TBL] [Abstract][Full Text] [Related]
6. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039 [TBL] [Abstract][Full Text] [Related]
7. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity. Schwartz Z; Bowe RB; Coleman M; Magro CM Ann Diagn Pathol; 2018 Dec; 37():57-61. PubMed ID: 30292067 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial. Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851 [TBL] [Abstract][Full Text] [Related]
9. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma. Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615 [TBL] [Abstract][Full Text] [Related]
10. Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases. Albany C; Einhorn L; Garbo L; Boyd T; Josephson N; Feldman DR Oncologist; 2018 Mar; 23(3):316-323. PubMed ID: 29222199 [TBL] [Abstract][Full Text] [Related]
11. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin. Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583 [TBL] [Abstract][Full Text] [Related]
12. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas. Bhatt G; Maddocks K; Christian B Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003 [TBL] [Abstract][Full Text] [Related]
13. Primary cutaneous follicle center lymphoma with diffuse CD30 expression: a report of 4 cases of a rare variant. Kempf W; Kazakov DV; Rütten A; Rupec RA; Talarcik P; Ballová V; Kerl K; Dummer R; Lautenschlager S; Zimmermann DR; Tinguely M J Am Acad Dermatol; 2014 Sep; 71(3):548-54. PubMed ID: 24836545 [TBL] [Abstract][Full Text] [Related]
14. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin. Nizamuddin I; Galvez C; Pro B Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726 [TBL] [Abstract][Full Text] [Related]
15. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. Kim M; Lee JO; Koh J; Kim TM; Lee JY; Jeon YK; Keam B; Kim DW; Lee JS; Heo DS Haematologica; 2021 Aug; 106(8):2277-2280. PubMed ID: 33792222 [No Abstract] [Full Text] [Related]